Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.

Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari R.

J Am Coll Cardiol. 2007 Jul 10;50(2):138-45. Epub 2007 May 22.

PMID:
17616297
[PubMed - indexed for MEDLINE]
Free Article
2.

Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.

Piscione F, Piccolo R, Cassese S, Galasso G, Chiariello M.

Catheter Cardiovasc Interv. 2009 Aug 1;74(2):323-32. doi: 10.1002/ccd.22017. Review.

PMID:
19360858
[PubMed - indexed for MEDLINE]
3.

Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

van 't Hof AW, Valgimigli M.

Drugs. 2009;69(1):85-100. doi: 10.2165/00003495-200969010-00006. Review.

PMID:
19192938
[PubMed - indexed for MEDLINE]
4.

Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials.

Piccolo R, Cassese S, Galasso G, Niglio T, De Rosa R, De Biase C, Piscione F.

Clin Res Cardiol. 2012 Nov;101(11):885-93. doi: 10.1007/s00392-012-0472-y. Epub 2012 May 16. Review.

PMID:
22588843
[PubMed - indexed for MEDLINE]
5.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Eur Heart J. 1998 Apr;19 Suppl D:D10-21. Review.

PMID:
9597518
[PubMed - indexed for MEDLINE]
6.

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA.

Am Heart J. 2004 Mar;147(3):457-62. Review.

PMID:
14999194
[PubMed - indexed for MEDLINE]
7.

Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.

Velianou JL, Al-Suwaidi J, Mathew V.

Am J Cardiovasc Drugs. 2002;2(5):315-22. Review.

PMID:
14727961
[PubMed - indexed for MEDLINE]
8.

Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.

Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C.

Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. Review.

PMID:
21718242
[PubMed - indexed for MEDLINE]
9.

Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state.

Kereiakes DJ.

Am J Cardiol. 1998 Apr 9;81(7A):49E-54E. Review.

PMID:
9551595
[PubMed - indexed for MEDLINE]
10.

Stenting and abciximab in primary angioplasty: a review of current status.

De Luca G, Suryapranata H, Piscione F, Barbato E, Chiariello M.

Ital Heart J. 2005 Nov;6(11):874-80. Review.

PMID:
16320920
[PubMed - indexed for MEDLINE]
11.

Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction--a meta-regression of randomized controlled trials.

Sethi A, Bajaj A, Bahekar A, Bhuriya R, Singh M, Ahmed A, Khosla S.

Catheter Cardiovasc Interv. 2013 Aug 1;82(2):171-81. doi: 10.1002/ccd.24653. Epub 2013 Mar 25. Review.

PMID:
22961908
[PubMed - indexed for MEDLINE]
12.

Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.

De Luca G, Suryapranata H, Grimaldi R, Chiariello M.

QJM. 2005 Sep;98(9):633-41. Epub 2005 Jul 22. Review.

PMID:
16040669
[PubMed - indexed for MEDLINE]
Free Article
13.

Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET.

Moliterno DJ, Chan AW.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):49S-54S. Review.

PMID:
12644341
[PubMed - indexed for MEDLINE]
14.

ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET).

Doggrell SA.

Expert Opin Pharmacother. 2001 Sep;2(9):1507-9. Review.

PMID:
11585028
[PubMed - indexed for MEDLINE]
15.

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.

Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ.

Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. Review.

PMID:
19755402
[PubMed - indexed for MEDLINE]
Free Article
16.

[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].

Fries R, Böhm M.

Med Klin (Munich). 2003 Apr 15;98(4):218-25. Review. German.

PMID:
12715145
[PubMed - indexed for MEDLINE]
17.

A comparison of therapeutic trends in myocardial infarction.

Milasinovic D, Teischinger L, Luerzer G, Mohl W.

Wien Klin Wochenschr. 2007;119(11-12 Suppl 1):15-9. Review. No abstract available.

PMID:
19618592
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk